

QIBA CT Volumetry Technical Committee Update Call

27 August 2012 at 11 AM CDT (GMT-5)

Call Summary

In attendance:

P. David Mozley, MD (Co-Chair)
James J. Conklin, MS, MD (Co-chair)
Hubert Beaumont, PhD
Andrew Buckler, MS
Barbara Croft, MD
Philip F. Judy, PhD
Michael McNitt-Gray, PhD
James Mulshine, MD

Guillaume Orioux
Gaurav Sawhney, MBA
Sarah Sherlock, PhD
Ann L. Scherzinger, PhD
Neil Steinmetz, MD, JD
Daniel C. Sullivan, MD
Luduan Zhang, PhD

RSNA:

Joe Koudelik
Madeleine McCoy

Update on Application for Continued External Funding

- Dr. Sullivan reported that the Statement of Work (SOW) has been developed with 6 objectives and supporting tasks.
 - The SOW was distributed to the Technical Committees and has been sent to NIH.

QIBA Posters for the RSNA 2012 Annual Meeting

- The poster topic and a leader for the development/printing process for 2012 needs to be determined.
 - Dr. Mozley will inquire with Merck Graphics Dept as to the software used to develop last year's poster.
 - The next Tech Cttee t-con will focus on the high-level objectives and adjusting the 2012 poster timeline.
 - A review of the NIBIB groundwork projects over the last 2 years, including a summary of the reports, the accomplished work and intentions for future developments, was suggested.
 - The deadline for submitting a print-ready file to RSNA HQ is November 1st.
- **QIBA CT Volumetry AdvDisease Profile v2.0**
 - Voting on release of the final Profile version for Profile Implementation is the next step in the development process.
 - RSNA Staff will distribute the latest Profile version to all CT Modality Committee (voting) Members.
 - The most current listing of the Modality Members can be found on the QIBA WIKI at: http://qibawiki.rsna.org/index.php?title=QIBA_Modality_Committees
 - The timeline for the Go/No Go vote is 8-9 working days.
 - Voting members will submit their vote directly to RSNA Staff.

Early Stage Lung Cancer Profile Writing Group Discussion (Dr. Mulshine)

- Goal of the effort
 - The work will be analogous to the AdvDisease Profile/Neoadjuvant efforts.
 - Profile to help assess clinically aggressive vs. non-aggressive cancers within the screening process (i.e., assess growth rate over a time interval).
 - Response assessment deemed priority, with screening a secondary focus.
 - The size of the nodules, slice thickness, volume, density as well as variation in measurement needs to be addressed.
 - Dr. Mulshine discussed the specifics of the claim language and will compose for distribution/feedback.
 - The next steps will be to create a workflow and gather supporting literature.
 - Consideration being given to utilizing the CT Advanced Disease Profile as a structural framework.
 - Drs. Judy and Mulshine will continue considerations of the involvement of the COPD/Asthma group in respect to the low dose of screening for emphysema.
 - The participants on this t-con were encouraged to notify RSNA Staff if they were interested in involvement with the writing group.
 - RSNA Staff will send the invitation letters to the invited participants. This letter will include a Doodle Poll to choose the first t-con date.

Next steps

- The next QIBA CT-VOL Tech Cttee t-con will be September 10th at 11am (CT)
- Dr. Mozley will inquire with Merck as to the software used to develop the 2011 RSNA Annual Meeting poster.
- RSNA Staff will initiate Go/No Go vote among the CT Modality Cttee voting members.
- RSNA Staff to send the invitation letters for the Early Stage Lung Cancer Profile Writing Group.